Inflammatory leucocyte infiltrates are associated with recovery in biopsy-proven acute interstitial nephritis: a 20-year registry-based case series

Ralph Wendt1,*, Jennifer Schliecker1,* and Joachim Beige1,2

1Division of Nephrology and Kuratorium for Dialysis and Transplantation (KfH) Renal Unit, Hospital St Georg, Leipzig, Germany and 2Department of Internal Medicine II, Division of Nephrology and Rheumatology, Martin-Luther-University Halle/Wittenberg, Halle (Saale), Germany

Correspondence and offprint requests to: Joachim Beige; E-mail: Joachim.Beige@sanktgeorg.de

*These authors contributed equally to this work.

ABSTRACT

Background. Acute interstitial nephritis (AIN) is a renal injury causing renal function deterioration and requiring renal replacement therapy (RRT) in a substantial number of cases. Therapy is based on withdrawal of suspicious causative drugs or the underlying diseases and/or steroid application if renal function is not restored after cessation of the underlying condition. Hard clinical evidence for augmenting steroid therapy is not available.

Methods. We reviewed the course and diagnosis for >20 years among all 1126 biopsied samples of our tertiary renal centre.

Results. 49 (4.4%) were diagnosed with primary AIN, corresponding to an annual incidence of 1/100 000 population; 17 out of 49 biopsy-proven AIN patients required short-term or long-term (n = 5) RRT. According to a combined outcome criterion of coming off dialysis and/or reaching serum creatinine <200 μmol/L, 19 patients reached recovery whereas 20 did not. Among 39 patients with a comprehensive clinical and histopathological data set, presence of cortical scars, AIN histological activity (acute leucocyte infiltrates) and proteinuria were baseline parameters discriminating significantly between groups with or without recovery. No associations with the presence of specific drugs were found. Therapeutic use of steroids was associated with a lower probability of recovery (P = 0.008), presumably due to inclusion bias.

Conclusions. Following our basic finding of the importance of histopathological parameters of acuity associated with recovery, we argue for the inauguration of grading measures to characterize this issue quantitatively and make it usable for future controlled investigations. Finally, we provide a suggestion for a therapeutic algorithm in the management of AIN.

Keywords: C-reactive protein, cortex, dialysis, interstitial, nephritis, nephrology, scars, steroid

INTRODUCTION

Acute interstitial nephritis (AIN) is a renal injury causing a decrease in renal function and is hallmarked by a leucocyte infiltrate in renal interstitium [1, 2]. Toxic and allergy-causing compounds such as all kinds of medication [3-25] or environmental substances, infectious agents, i.e. bacteria (Legionella, Leptospira, Streptococci, Corynebacteriae, Mycoplasma, etc.)
and viruses (hantavirus, measles, Epstein–Barr virus, cytomegalo-
ivirus, HIV) [26], and a variety of autoimmune disorders [27] (e.g. systemic lupus erythematosus [28, 29], Sjögren’s syndrome, sarcoi-
dosis [30], immunoglobulin G4-related disease) play a key role in the
pathogenesis of this disease. Among the drugs trig-
gerating AIN, there has been increasing awareness about the role
of proton pump inhibitors (PPIS) [3, 14, 21, 22, 31, 32] in addition
to non-steroidal anti-inflammatory drugs (NSAIDs) [3] and anti-
biotics [13] as causative agents and even inducers of chronic
kidney disease (CKD) [33].

Diagnosing AIN is generally challenging. The triad of rash,
fever and eosinophilia is rarely seen together (<10%) [34]. There
is no specific symptom with a useful predictive value for AIN.
The occurrence of drug rash is often interpreted as a hint of AIN
in association with acute kidney failure, but actually, it is only
seen in 15–50% of cases [35] and mostly in antibiotic exposure,
and rarely in patients on PPIS or NSAIDs.

The predictive value of fractional excretion of sodium is
lower than generally thought to be. Urine microscopy can be
misleading and urine eosinophils can be found in a variety
of kidney diseases besides AIN. In the largest recent study, 63 out
of 91 patients with biopsy-proven AIN had no evidence of urine
eosinophils at all, leaving urine eosinophils with low sensitivity
in diagnosing AIN [36]. The diagnostic performance of other mo-
dalities like imaging procedures (ultrasound, computed
tomography scan, gallium scintigraphy) is not satisfactory. The
only definite diagnostic tool is kidney biopsy.

All variations of outcomes starting from mild and intermit-
tent acute kidney injury (AKI), including partial recovery, up
to progression to end-stage renal disease (ESRD) necessitating re-
nal replacement therapy (RRT, 5–10% of cases) can be seen.
Therapy is usually based on steroids with primary cessation of
the suspected causing agent. For augmenting steroid therapy,
no randomized controlled trial (RCT) is available and observa-
tions surveying outcomes are inconclusive. There are case se-
ries supporting steroid therapy in which the time to recovery or
the proportion of patients remaining on dialysis was lower if
steroid therapy was applied [37]. Recently a large retrospective
study from London with 187 cases of AIN (158 treated with ste-
roids) suggested a benefit of steroid use with greater improve-
ment in estimated glomerular filtration rate and fewer patients
progressing to ESRD [38]. Other retrospective series demon-
strated no benefit from steroid therapy [1, 39].

To survey our experience spanning two decades with AIN,
we identified all biopsy-proven AIN between 1992 and 2012 in
the metropolitan area of Leipzig (Saxony, Germany) and retro-
spectively analysed symptoms, causes, therapy regimes and re-
nal outcomes. We aimed to identify the risks and therapeuti-
cal factors influencing the course of AIN.

MATERIALS AND METHODS

Patient population, data acquisition and handling

Over the observation period from 1992 to 2012, two genera-
tions of senior nephrologists were in charge of indicating renal biopsy
in all presenting patients. A biopsy was performed in patients
primarily presented with acute kidney failure or in patients
with suspected AIN who did not respond to drug cessation and/
or steroid therapy. Overall biopsy incidence rose over the years
from 18 biopsies in 1992 to 84 in 2012, yielding a total of 1126 bi-
opsy cases over the 20-year period of investigation. The hospital
is one of two renal centres in Leipzig and covers 50% of the over-
al metropolitan population of 700 000 people.

Registry structure

After the biopsy procedure, all tissue samples were shipped to a
specialized kidney histopathology laboratory (University Hospital Hamburg-Eppendorf, Div. of Renal Histopathology). For
clinical diagnosis, a written report was generated. All reports
were subjected to a structured register (n = 1126). The reports
were collected in 2014 and classified by predefined diagnosis
and presence of the following histopathological features: neph-
rosclerosis, cortical scars, focal inflammation, destructive in-
jury, tubulopathy, haematuria and leucocyturia. AIN ‘activity’
was classified into:

(i) High activity: biopsies showing only acute inflammatory
infiltrates.

(ii) Intermediate activity: biopsies showing both acute inflil-
trates but also signs of chronic changes.

(iii) No activity: biopsies showing non-active AIN with mainly
chronic damage of expired AIN.

Clinical records were retrieved and classified for C-reactive
protein, proteinuria, serum creatinine (Crea), urine cytol-
ytical findings, presence of the presumably causing medication and
application of steroid therapy.

Outcome parameter

To investigate the outcomes, a combined recovery criterion
composed of changing renal function and a remaining necessity
for RRT was created. Patients who reached (known or antici-
pated) pre-AIN baseline renal function were considered to have
‘complete recovery’. Those coming-off dialysis and/or reaching
Crea <200 µmol/L were considered to have ‘partial recovery’ and
those with no improvement in renal function and/or remaining
on RRT were considered to have ‘no recovery’.

Statistics

Descriptive statistics of patient data with pseudonym ID num-
bersons were produced using standard procedures with the SPSS
version 13.0 program package. In logistic regression analyses,
covariates were analysed by a non-conditional overall model
using outcome as ‘dependent’. Group comparison of categorical
values was computed by contingency tables and chi-square,
while numerical values were compared by one-factorial analy-
sis of variance and independent t-test. Time-on-RRT analysis
was conducted by univariate procedures (Kaplan–Meier) and di-
ichotomized for trimodal population strata depending on base-
line status of activity and use of steroids. Start time was the
first dialysis date (survival plots) and end time was the last dial-
ysis date. All events leading to the loss of follow-up other than
endpoints (change to life-sustaining renal function, and end of
observation in December 2014) were censored and indicated by
crosses within the survival plot lines. Survival plots were trunc-
ated at 10 years.

RESULTS

Among 49 patients with biopsy-proven AIN during the observa-
tion period (out of a total number of 1126 renal biopsies), a com-
plete data set of outcome surrogates could be identified in 39
patients. The finding of 49 AIN patients over the 20-year period
corresponded to an annual incidence of 1 patient per 100 000
inhabitants and 4.4% of patients with indication to perform a
biopsy.
Table 1. Baseline characteristics of the population by groups of AKI recovery

| Anthropometric feature         | Recovery                      | P     |
|-------------------------------|------------------------------|-------|
|                               | Any (n = 30)                 | No (n = 9) |
| Age (years)                   | 51.5 ± 20.4                  | 52.4 ± 18.6 | 0.49 |
| Male                          | 15 (50)                      | 7 (77.8)  | 0.14 |
| Crea baseline (µmol/L)        | 119 ± 48.3                   | 174 ± 61.1 | 0.85 |
| BP (mmHg)                     | 150/84 ± 29.8/12.4           | 159/82 ± 25.1/12.3 | 0.46/0.7 |
| BMI (kg/m²)                   | 28 ± 6.7                     | 25.4 ± 5.9 | 0.75 |
| Proteinuria (g/g Crea)        | 1.43 ± 2.15                  | 3.22 ± 5.03 | 0.003 |
| Steroid therapy              | 13 (43.4)                    | 8 (88.8)  | 0.008 |
| Pulse                         | 2 (6.7)                      | 4 (44.4)  |     |
| Weight-adapted               | 11 (36.7)                    | 4 (44.4)  |     |

Values are represented as n (%) or mean ± SD.

Baseline anthropometric results by the presence of recovery are given in Table 1. Patients achieving complete or partial recovery had a lower baseline Crea of 119 ± 48 µmol/L compared with 174 ± 61 µmol/L (P = 0.85) in patients not reaching recovery. The average maximal Crea was not different amongst patients with any kind of recovery versus patients with no recovery (415 ± 295 µmol/L versus 543 ± 223 µmol/L, P = 0.34).

There was no difference in blood pressure or body mass index (BMI) between those two groups. Proteinuria was significantly higher in patients with no recovery than in patients with any kind of recovery (3.22 ± 5.03 g/g Crea versus 1.43 ± 2.15 g/g Crea, P = 0.003).

In total, 17 patients needed RRT. Eight biopsy-proven AIN patients had intermittent dialysis no longer than 2 weeks, four patients between 2 weeks and 30 months and five patients remained on maintenance dialysis until the end of observation (Table 2). A 78-year-old man died 2 years after coming off dialysis due to renal carcinoma (considered partial recovery) and a 79-year-old woman died after AIN on dialysis due to fungal septicaemia (considered no recovery). Including patients coming off dialysis, 20 patients reached complete recovery, 10 partial recovery and 9 no recovery; 37% of patients reaching any kind of recovery needed temporary RRT compared with 67% of patients in need of RRT with no recovery (P < 0.001).

The presence of cortical scars (53% versus 100%, P = 0.01) and active interstitial inflammation (70% versus 44%, P = 0.01) were histological baseline parameters discriminating significantly between groups with or without AIN recovery (Table 3). There were no differences in the presence of nephrosclerosis or tubulopathy and no difference in the presence of urinary markers, e.g. haematuria or leucocyturia.

Among the drugs used by patients with diagnosed biopsy-proven AIN in our cohort (Table 4), RAAS inhibitors were the most common medication (22 out of 39 patients in the entire cohort with no difference between recovery groups). Antibiotics (20% versus 11%, P = 0.054) and NSAIDs (17% versus 0%, P = 0.19) were more often used in patients that achieved some kind of recovery compared with patients with no recovery. PPIs, on the other hand, were more often found in patients with worse renal outcome compared with patients achieving some kind of recovery (56% versus 27%, P = 0.11).

By logistic regression of baseline variables, using recovery as ‘dependent’, baseline Crea remained in the model (P = 0.048) and the presence of scars showed a tendency to influence a
forward conditional outcome model (P = 0.08). No associations of other anthropometric parameters, nor presence of specific drugs (Table 4), except a trend for NSAIDs and PPIs, were found. Steroids were more often applied to patients with the outcome ‘no recovery’ than to patients with some kind of recovery (89% versus 43%, P = 0.008). Therapeutic use of steroids was associated with a lower probability of recovery (P = 0.008).

DISCUSSION

The present observation provides a long-term and population-based insight into the epidemiology and prognosis of AIN while being retrospective in nature, incorporating all the pitfalls of such a design. It is the only investigation providing a prognostic evaluation by detailed analysis of patient’s time on dialysis. The annual AIN incidence of 1/100 000 is comparable to recent population-based data found in Scotland [40] and France [16], and earlier data from Germany [41]. With 17 patients temporarily needing and 5 patients remaining on RRT, AIN requiring biopsy diagnosis must be considered as a severe and life-threatening disease, comparable to crescentic glomerulonephritis. Suspected causes of AIN were similar to earlier data showing suspicious drugs present in >70% of patients. It is, however, intriguing to suppose the effects of drugs like PPI because they are used in a multitude of patients and the question of causality is hard to decide. This is best elucidated by our result, that inhibitors of the renin–angiotensin system were the most common drugs used in patients diagnosed with AIN. Only one nested-case epidemiological study provides stronger evidence of a 70% higher incidence of AKI in patients treated with PPIs [42]. Our study found NSAIDs to be used more frequently in patients recovering from AIN–AKI, although this trend was not statistically significant. The trend for worse renal outcomes among patients using PPIs and better outcomes for users of NSAIDs and antibiotics may be explained by a higher awareness of treating physicians of the causative association between NSAIDs/antibiotics and AIN and lower awareness between the link of PPIs with AIN. The latter might lead to delay in diagnosis and failure to stop the causative drug, and therefore worsen renal outcome.

Renal cortex scars and proteinuria were significantly associated with a worse renal outcome (not reaching recovery) even given the small numbers of observation, which was similarly described in another German study [41]. AIN histological activity (without scars) was associated with recovery showing more acute leucocyte infiltrations in patients recovering from AIN and those coming off RRT if needed (Figure 1). Steroids were more frequently used in those patients not reaching AIN recovery and/or coming off RRT (Figure 2). This finding has to be interpreted cautiously, with awareness of significant indication bias. More severe disease is more likely to trigger steroids use independent of inflammatory acuity, at least given current clinical considerations. We confirm results from other studies by failing to show a positive effect of steroid use on renal outcomes.

In clinical settings, steroids are widely used particularly in patients without renal improvement after cessation of the presumably causative drug, supposedly without much regard to acuity. However, from a pathophysiological point of view, looking at the renal leucocyte infiltrate before deciding on immunosuppressive therapy makes a lot of sense. The histopathological hallmark of AIN consists of an interstitial inflammatory infiltrate composed mainly of lymphocytes together with plasma cells and macrophages. Glucocorticoids (GCs) are potent inhibitors of those inflammatory processes. Their anti-inflammatory and immunomodulatory effects are mediated predominantly by genomic mechanisms, either by direct binding of the GC/GC-receptor complex to GC responsive elements in the promoter region of genes or by non-genomic mechanisms, responsible for some regulating effects, which arise a few minutes after administration [43]. In this way, they inhibit several proinflammatory molecules, such as cytokines, chemokines, arachidonic acid metabolites and adhesion molecules. Therefore, GCs can reduce and reverse the mechanism of tubulointerstitial inflammation and additionally exhibit direct effects on the infiltrating lymphocytes, e.g. by induction of apoptosis [44, 45].

Questions remain on how to manage therapy with special focus on how to adjust therapy decisions to histopathological features (acuity versus scaring), when to treat (waiting for renal improvement after cessation of the presumably causative drug or proceeding with treatment after clinical suspicion of AIN),
and what dosage of steroids should be used and for how long. Concerning steroid timing, a recent RCT in biopsy-proven AIN revealed no outcome difference in patients randomized to oral or pulse prednisolone with treatment duration for >3 weeks followed by rapid tapering over another 3 weeks [46]. A significant benefit of steroid usage in patients with an early start of treatment within 7 days after the withdrawal of the offending drug was suggested [47]. Another study emphasizes worse prognosis with delayed steroid treatment and most interestingly points out no benefit from longer duration of steroid therapy (>3 weeks) on outcome [37]. More acute onset of disease with signs of acute inflammation in biopsy without extensive chronic damage had a higher probability of renal recovery [37]. This is in line with our result of the association of AIN histological activity with recovery and the higher likelihood of coming off RRT and recovery from AIN in those patients with more acute leucocyte infiltrations.

Due to the lack of any hard evidence and the low likelihood of having an RCT on AIN therapy soon, we would like to propose an algorithm for clinical management in cases with suspected drug-induced AIN (Figure 3). This algorithm is our personal opinion but it might help develop currently lacking widely accepted therapy guidelines on AIN.

We do support an important role for renal biopsy for gaining a definite diagnosis and prognostic information. Renal biopsy is a safe procedure, especially in experienced centres, and complication rates can be as low as 2% [48]. The risk of complications is higher in the setting of AKI [49], mainly due to the presence of increased risk factors [50]. We do postpone renal biopsy for 5–7 days in the presence of aspirin medication (while already treating the patient in case of suspected AIN with severe AKI) even though this practice is not supported by hard evidence and some data suggest no elevated bleeding risk in performing renal biopsy without stopping aspirin [51]. Currently, there is no consensus on the interpretation of the available data and guidelines that standardize biopsy practices are lacking [52].

Of course, our investigation suffers from several weaknesses. First, similar to basically all studies on AIN, it employs retrospective risk factor retrieval and therapy. With such an approach, no high-grade clinical evidence, particularly regarding the usefulness of therapy, can be reached. Because this study adds a further negative observation on steroid therapy success in AIN, we see an urgent need to conduct a collaborating multicentre, randomized trial on this question. Secondly, although we found some disproportionate distribution of risk factors and compounds (NSAIDs), these findings are hard to rate because of the small incidence over the observation period of 20 years. It is therefore necessary to combine the design of such a trial with a structured registry evaluating the systematic occurrence of symptoms and histological features in a satisfactory number of patients (n>300). Thirdly, following our finding of the importance of cortex scars and AIN activity (acuity of infiltrates), we want to stress the perspective utility of a histological scoring system (comparable to Banff or Oxford scales in other diseases) for a quantitative description of interstitial findings.

In summary, we present an observational study evaluating clinical presentation, histological features, therapy and outcome of AIN in a renal centre for >20 years. We found proteinuria, presence of renal cortex scars and acuity of histological inflammation to be the significant prognostic factors. Steroid therapy had an inverse association with outcome, presumably due to inclusion bias. Therapy for AIN should not be delayed, as the highest chance of recovery can be attributed to the early
stages of the disease with acute inflammatory signs and low chronic damage in the biopsy.

ACKNOWLEDGEMENTS

We greatly appreciate the contribution of Prof. Udo Helmchen and Prof. Thorsten Wiehr, former and current head of Division of Renal Histopathology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, in providing histopathological analysis, and of Florian Fahr for collecting registry data on renal histopathological results. We also thank Ursula Perrier for her language support.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Bhaumik SK, Kher V, Arora P. Evaluation of clinical and histologic prognostic markers in drug-induced acute interstitial nephritis. Ren Fail 1996; 18: 97–104
2. Buysen JG, Houthoff HJ, Krediet RT et al. Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 1990; 5: 94–99
3. Leonard CE, Freeman CP, Newcomb CW et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 2012; 21: 1155–1172
4. Alexopoulos E. Drug-induced acute interstitial nephritis. Ren Fail 1998; 20: 809–819
5. Linton AL, Clark WF, Driedger AA et al. Acute interstitial nephritis due to drugs: review. Ann Intern Med 1980; 93: 735–741
6. Pommer W, Offermann G, Schultze G et al. [Acute interstitial nephritis caused by drugs]. Dtsch Med Wochenschr 2008; 108: 783–788
7. Appel GB. A decade of penicillin related acute interstitial nephritis–more questions than answers. Clin Nephrol 1980; 13: 151–154
8. Augusto J-F, Sayegh J, Simon A et al. A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant 2009; 24: 2940–2942
9. Baldwin D, Prince M, Marshall S et al. Regulation of insulin receptors: evidence for involvement of an endocytotic internalization pathway. Proc Natl Acad Sci USA 1980; 77: 5975–5978
10. Burkhart R, Shah N, Lewin M. Sildenafil induced acute interstitial nephritis. Case Rep Nephrol 2010; 2: 390–396
11. Calvino J, Romero R, Pintos E et al. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol 1998; 49: 265–267
12. Chatzkyrykou C, Hamwi I, Clajus C et al. Biopsy proven acute interstitial nephritis after treatment with moxifloxacin. BMC Nephrol 2010; 11: 19
13. D’Agati VD, Theise ND, Pirani CL et al. Interstitial nephritis related to nonsteroidal anti-inflammatory agents and beta-lactam antibiotics: a comparative study of the interstitial infiltrates using monoclonal antibodies. Mod Pathol 1989; 2: 390–396
14. Geevasinga N, Coleman PL, Webster AC et al. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006; 4: 597–604
15. Kaye WA, Passero MA, Solomon RJ et al. Cimetidine-induced interstitial nephritis with response to prednisone therapy. Arch Intern Med 1983; 143: 811–812
16. Leven C, Hudier L, Picard S et al. Prospective study of drug-induced interstitial nephritis in eleven French nephrology units. Presse Med 2014; 43: e369–e376
17. Markowitz GS, Tartini A, D’Agati VD. Acute interstitial nephritis following treatment with anorectic agents phentermine and phenidimetrime. Clin Nephrol 1998; 50: 252–254
18. Murray KM, Keane WR. Review of drug-induced acute interstitial nephritis. Pharmacotherapy 1992; 12: 462–467
19. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol 2010; 6: 461–470
20. Pitone JM, Santoro JJ, Biondi RJ et al. Cimetidine-induced acute interstitial nephritis. Am J Gastroenterol 1982; 77: 169–171
21. Sampathkumar K, Ramalingam R, Prabakar A et al. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol 2013; 23: 304–307
22. Sierra F, Suarez M, Rey M et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007; 26: 545–553
23. Smith WR, Neill J, Cushman WC et al. Captopril-associated acute interstitial nephritis. Am J Nephrol 1989; 9: 230–235
24. Soni N, Harrington JW, Weiss R et al. Recurrent acute interstitial nephritis induced by azithromycin. Pediatr Infect Dis J 2004; 23: 965–966
25. Woodruff AJ, Weldon M, Meadows R et al. Acute interstitial nephritis following ampicillin hypersensitivity. Med J Aust 1975; 1: 65–68
26. Mirabella M, Taramasso L, Nicolini LA et al. Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature. Clin Nephrol Case Stud 2018; 6: 31–35
27. Rodriguez-Perez JC, Cruz-Alamo M, Perez-Aciego P et al. Clinical and immune aspects of idiopathic acute tubulointerstitial nephritis and uveitis syndrome. Am J Nephrol 1995; 15: 386–391
28. Park MH, D’Agati V, Appel GB et al. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986; 44: 309–319
29. Yung S, Chan TM. Molecular and immunological basis of tubulo-interstitial injury in lupus nephritis: a comprehensive review. Clin Rev Allergy Immunol 2017; 52: 149–163
30. Mignon F, Mery JP, Mougenot B et al. Granulomatous interstitial nephritis. Adv Nephrol Necker Hosp 2004; 13: 219–245
31. Harmark L, van der Wiel HE, de Groot MCH et al. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 2007; 64: 819–823
32. Simpson IJ, Marshall MR, Pilmore H et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton) 2006; 11: 381–385
33. Xie Y, Bowe B, Li T et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016; 27: 3153
34. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2004; 19: 8–11
35. Perazella MA. Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician. Clin Nephrol 2014; 81: 381–388
36. Muriithi AK, Leung N, Valeri AM et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 2015; 87: 458–464
37. Fernandez-Juarez G, Perez JV, Caravaca-Fontán F et al. Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol 2018; 13: 1851–1858
38. Prindecki M, Tanna A, Salama AD et al. Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. Clin Kidney J 2017; 10: 233–239
39. Koselj M, Kveder R, Bren AF et al. Acute renal failure in patients with drug-induced acute interstitial nephritis. Ren Fail 1993; 15: 69–72
40. Valluri A, Hetherington L, Mcquarrie E et al. Acute tubulointerstitial nephritis in Scotland. QJM 2015; 108: 527–532
41. Schwarz A, Krause PH, Kunzendorf U et al. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54: 179–190
42. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol 2013; 14: 150
43. Buttgereit F, Straub RH, Wehling M et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50: 3408–3417
44. Lanza L, Scudeletti M, Puppo F et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol 2007; 103: 482
45. Webster JC, Huber RM, Hanson RL et al. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology 2002; 143: 3866
46. Kim MJ, Heim M, Mayr M. Effect of corticosteroids during ongoing drug exposure in pantoprazole-induced interstitial nephritis. Nephrol Dial Transplant 2010; 25: 1716–1719
47. González E, Gutiérrez E, Galeano C et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008; 73: 940–946
48. Tøndel C, Vikse BE, Bostad L et al. of Percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988–2010. Clin J Am Soc Nephrol 2012; 7: 1591–1597
49. Corapi KM, Chen JLT, Balk EM et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 2012; 60: 62–73
50. Korbet SM, Gashiri CN, Evans JK et al. Risk of percutaneous renal biopsy of native kidneys in the evaluation of acute kidney injury. Clin Kidney J 2018; 11: 610–615
51. Lees JS, McQuarrie EP, Mordi N et al. Risk factors for bleeding complications after nephrologist-performed native renal biopsy. Clin Kidney J 2017; 10: 573–577
52. Lees JS, McQuarrie EP, Mackinnon B. Renal biopsy: it is time for pragmatism and consensus. Clin Kidney J 2018; 11: 605–609